Health Technology Access Pool (HTAP) by the WHO

By HEOR Staff Writer

February 19, 2024

Health Technology Access Pool

WHO’s Health Technology Access Pool

The World Health Organization (WHO) has recently announced the Health Technology Access Pool (HTAP). This serves as a successor to the COVID-19 Technology Access Pool (C-TAP). This initiative marks a significant step towards more equitable access to a broad range of health products. The aim is to enhance global health security.

From C-TAP to HTAP: A Journey of Evolution

Launched in May 2020, C-TAP was a collaborative effort between WHO, the Government of Costa Rica, and other partners. This platform was instrumental in providing a forum for technology partners to share intellectual property, knowledge, and data voluntarily. Despite the challenges of establishing a novel mechanism amidst a pandemic, C-TAP managed to secure six transparent, non-exclusive global licences involving 15 technologies that span research and development (R&D) tools, diagnostics, and vaccines.

Building on C-TAP’s Foundation

HTAP is built on the foundation laid by C-TAP but incorporates structural, process, and other changes to attract and support a diverse range of priority technologies more effectively. It aims to promote access to health products that respond to public health priorities, including pandemic preparedness, and are relevant during and outside health emergencies.

Amplifying Public Health Value

HTAP investments will amplify the public health value and increase the attractiveness of licensed technologies to recipient manufacturers. This approach will realise greater market opportunities and financial sustainability. The announcement on the licensing of a rapid diagnostic test platform technology serves as an example of such an approach.

The Future of HTAP: Awaiting Further Details

In the first quarter of 2024, WHO will publish further details on how HTAP will operate and the technologies it will target. Plans are in place to officially launch HTAP in the second quarter of 2024. In the interim, WHO will adopt the principles and approach described above in evaluating opportunities to secure health technologies and expand regional or global production capacity.

Reference url

Recent Posts

clinical trial monitoring
Clinical Trial Monitoring: Insights from Q1 2026 EU/EEA Report

By HEOR Staff Writer

May 22, 2026

Clinical trial monitoring shows that in the first quarter of 2026, an average of 208 new clinical trial applications were submitted monthly through the Clinical Trials Information System, yielding 668 total submissions of which 538 received authorisation. The median time from submission to decisi...
EUDAMED Implementation 2026
EUDAMED Implementation 2026: Key Changes and National Adaptations
The EUDAMED Implementation 2026 will require mandatory use of four key modules in the European database on medical devices from 28 May 2026. These cover registration of economic operators, device registration via UDI, notified bodies and certificates, plus market surveillance, following earlier v...
TrumpRx.gov expansion
TrumpRx.gov Expansion: Enhancing Medication Price Transparency and Competition
TrumpRx.gov expansion marks a major step toward greater medication price transparency, as detailed in President Donald J. Trump’s announcement to list more than 600 generic drugs on the platform. Patients can now compare competitive cash prices from Amazon Pharmacy, Cost Plus Drugs, and GoodRx fo...